

REMARKS

This paper supplements Applicants' March 4, 2008 Amendment Under 37 C.F.R. §1.115 that was in reply to the December 21, 2007 Office Communication. The purpose of this paper is to provide Applicants' three submissions as follows:

- A. Petition For Unintentionally Delayed Claim Of Priority Under 37 C.F.R. §1.78(a)(3) [Appendix A];
- B. Submission Of Sequence Listing [Appendix B]; and
- C. New replacement Figure 2 [Appendix C].

Although neither their priority claim or sequence listing was an issue in the December 21, 2007 Office Communication, Applicants are making these submissions because similar submissions were made in other related applications. It is also believed that the subject matter claimed in the present application is close to allowable condition.

In further detail, Applicants' Petition For Unintentionally Delayed Claim Of Priority Under 37 C.F.R. §1.78(a)(3) is attached as Appendix A, and it also includes:

- 1. Substitute Specification [Appendix 1]; and
- 2. Marked Up Copy of the Specification [Appendix 2].

Applicants' Submission Of Sequence Listing [Appendix B] includes an attached paper copy [Appendix 1] and attached computer readable copy of the Sequence Listing [Appendix 2], together with their Amendment In Connection With Submission Of Replacement Sequence Listing [Appendix 3].

Dakai Liu and Elazar Rabbani

Serial No. 09/046,840

Filed: March 24, 1998

Page 4 [Supplemental Reply To Applicants' March 4, 2008 Amendment Under 37
C.F.R. §1.115] – March 18, 2008

Finally, Applicants are also submitting herewith attached as Appendix C a replacement Figure 2 with proper SEQ ID NO identifiers listed thereon.

Applicants respectfully request that the above submissions attached hereto be entered and made of record in this application.

* * * * *

Dakai Liu and Elazar Rabbani

Serial No. 09/046,840

Filed: March 24, 1998

Page 5 [Supplemental Reply To Applicants' March 4, 2008 Amendment Under 37 C.F.R. §1.115] – March 18, 2008

SUMMARY AND CONCLUSIONS

No claims have been amended, added or canceled by this paper, the purpose of which is to make submissions relative to Applicants' claim for priority and their submission of sequence listing and a replacement Figure 2.

No fee or fees are believed due for filing this paper (Supplemental Reply). Fees are authorized in Applicants' priority claim and their submission of sequence listing. No other fee or fees are believed due in connection with this paper or the accompanying submissions. In the event that any other fee or fees are due, however, the Patent and Trademark Office is authorized to charge the amount of any such fee(s) to Deposit Account No. 05-1135, and to credit any overpayment thereto.

Applicants respectfully request early allowance of their application. Should it be deemed helpful or necessary, the Examiner is respectfully invited to telephone the undersigned at (212) 583-0100 to discuss the subject application.

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

ENZO THERAPEUTICS, INC.
c/o Enzo Biochem, inc.
527 Madison Avenue, 9th Floor
New York, New York 10017
Tel.: (212) 583-0100
Fax.: (212) 583-0150